Evidence map›Paper›PMID 20514026›Full record

ArticleOncogene2010

The RASSF8 candidate tumor suppressor inhibits cell growth and regulates the Wnt and NF-kappaB signaling pathways.

F E Lock, N Underhill-Day, T Dunwell, D Matallanas, W Cooper, L Hesson, A Recino, A Ward, T Pavlova, E Zabarovsky and 5 more

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 1 synthesis or guideline pooled it, 84 citations in OpenAlex.

  1. A Number of the N-terminal RASSF Family: RASSF7.Anti-cancer agents in medicinal chemistry · 2024
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. The tumor suppressor RASSF8: A WAVE interaction partner controlling migration and cohesion of invasive border cells inProceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  7. Article
  8. Review
  9. Non-Coding RNAs as Key Regulators in Lung Cancer.International journal of molecular sciences · 2023
    Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 3 countries.

F E LockDepartment of Medical and Molecular Genetics, Institute of Biomedical Research, University of Birmingham, Birmingham, UK.
N Underhill-Day
T Dunwell
D Matallanas
W Cooper
L Hesson
A Recino
A Ward
T Pavlova
E Zabarovsky
M M Grant
E R Maher
A D Chalmers
W Kolch
F Latif
University of Birmingham · GBUniversity of Bath · GBKarolinska Institutet · SEUniversity College Dublin · IE

Funding

Cancer Research UKMedical Research Council
6 · The paper itself

Abstract

The Ras-assocation domain family (RASSF) of tumor suppressor proteins until recently contained six proteins named RASSF1-6. Recently, four novel family members, RASSF7-10, have been identified by homology searches for RA-domain-containing proteins. These additional RASSF members are divergent and structurally distinct from RASSF1-6, containing an N-terminal RA domain and lacking the Sav/RASSF/Hpo (SARAH) domain. Here, we show that RASSF8 is ubiquitously expressed throughout the murine embryo and in normal human adult tissues. Functionally, RNAi-mediated knockdown of RASSF8 in non-small-cell lung cancer (NSCLC) cell lines, increased anchorage-independent growth in soft agar and enhanced tumor growth in severe combined immunodeficiency (SCID) mice. Furthermore, EdU staining of RASSF8-depleted cells showed growth suppression in a manner dependent on contact inhibition. We show that endogenous RASSF8 is not only found in the nucleus, but is also membrane associated at sites of cell-cell adhesion, co-localizing with the adherens junction (AJ) component beta-catenin and binding to E-cadherin. Following RASSF8 depletion in two different lung cancer cell lines using alternative small interfering RNA (siRNA) sequences, we show that AJs are destabilized and E-cadherin is lost from the cell membrane. The AJ components beta-catenin and p65 are also lost from sites of cell-cell contact and are relocalized to the nucleus with a concomitant increase in beta-catenin-dependent and nuclear factor-kappaB (NF-kappaB)-dependent signaling following RASSF8 depletion. RASSF8 may also be required to maintain actin -cytoskeletal organization since immunofluorescence analysis shows a striking disorganization of the actin- cytoskeleton following RASSF8 depletion. Accordingly, scratch wound healing studies show increased cellular migration in RASSF8-deficient cells. These results implicate RASSF8 as a tumor suppressor gene that is essential for maintaining AJs function in epithelial cells and have a role in epithelial cell migration.

Indexed as

Adherens JunctionsAnimalsCadherinsCell Line, TumorCell MovementCell ProliferationCytoskeletonHumansMiceMice, SCIDNF-kappa BPromoter Regions, GeneticSignal TransductionTranscription Factor RelATumor Suppressor ProteinsWnt ProteinsCadherinsNF-kappa BRASSF8 protein, humanTranscription Factor RelATumor Suppressor ProteinsWnt Proteins

Identifiers

PMID20514026
OpenAlexW2063907721

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.